Trial Profile
Phase I Study of Venetoclax Plus DA-EPOCH-R for the Treatment of Aggressive B-Cell Lymphomas
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 26 Aug 2022
Price :
$35
*
At a glance
- Drugs Venetoclax (Primary) ; Cyclophosphamide; Doxorubicin; Etoposide; Prednisone; Rituximab; Vincristine
- Indications B-cell lymphoma; Burkitt's lymphoma; Diffuse large B cell lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions
- Acronyms V+DA-EPOCH-R
- 23 Aug 2022 Status changed from active, no longer recruiting to completed.
- 20 Sep 2021 Planned End Date changed from 1 Aug 2021 to 1 Dec 2021.
- 23 Sep 2020 Planned End Date changed from 1 Aug 2020 to 1 Aug 2021.